Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3611-3619

  Gradishar, William J ^a   Krasnojon, Dimitry ^a   Cheporov, Sergey ^a   Makhson, Anatoly N ^a   Manikhas, Georgiy M ^a   Clawson, Alicia ^a   Bhar, Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; TAXOID;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; ADENOCARCINOMA; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; PROBABILITY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68949114599     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.5397     Document Type: Article

References (26)

1. Conlin AK, Seidman AD: Taxanes in breast cancer: An update. Curr Oncol Rep 9:22-30, 2007
2. Ferguson T, Wilcken N, Vagg R, et al: Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4:CD004421, 2007
3. Friedrich M, Diesing D, Villena-Heinsen C, et al: Taxanes in the first-line chemotherapy of metastatic breast cancer: Review. Eur J Gynaecol Oncol 25:66-70, 2004
4. Garcia M, Jemal A, Ward EM, et al: Global Cancer Facts and Figures 2007. Atlanta, GA, American Cancer Society, 2007
5. Ries LAG, Eisner MP: Cancer of the female breast, in Ries LAG, Keel GE, Eisner MP, et al (eds): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD, National Cancer Institute, NIH publication 07-6215, 2007, pp 101-110
6. Mayer EL, Burstein HJ: Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21:257-272, 2007
7. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 22:2061-2068, 2004
8. Verrill MW, Lee J, Cameron DA, et al: Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol 25:33s, 2007 (suppl; abstr LBA1005)
9. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008
10. Harries M, Ellis P, Harper P: Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 23:7768-7771, 2005
11. Hudis C: Testing chemotherapy for breast cancer: Timing is everything. J Clin Oncol 23:5434-5436, 2005
12. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005
13. Rivera E, Mejia JA, Arun BK, et al: Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455-1461, 2008
14. Gradishar WJ: Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 7:1041-1053, 2006
15. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803, 2005
16. Henderson IC, Bhatia V: Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 7:919-943, 2007
17. Pinder MC, Ibrahim NK: Nanoparticle albuminbound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc) 42:599-604, 2006
18. Desai N, Trieu V, Yao Z, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophorfree, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324, 2006
19. Nyman DW, Campbell KJ, Hersh E, et al: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793, 2005
20. Blum JL, Savin MA, Edelman G, et al: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7:850-856, 2007
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Oshaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001
23. Lara PN Jr, Redman MW, Kelly K, et al: Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials. J Clin Oncol 26:463-467, 2008
24. Desai N, Trieu V, Hawkins M, et al: Improved effectiveness of nab-paclitaxel versus docetaxel in various xenografts as a function of HER2 and SPARC status. Presented at the 18th EORTC-NCIAACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, November 7-10, 2006
25. Desai N, Trieu V, Hwang L, et al: HER2 and SPARC status in tumors play an important role in the relative effectiveness of nanoparticle albumin-bound (Nab) paclitaxel versus polysorbate-based docetaxel. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
26. Desai NP, Trieu V, Hwang LY, et al: Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19:899-909, 2008